Previous studies have demonstrated that isocitrate dehydrogenase (IDH) mutations have a considerable impact on the prognosis of patients with GBM,2, 3 and the role of IDH mutations has been reinforced in classifying IDH wild‐type GBM in the 2021 World Health Organization classification of tumors of the central nervous system.4 Here, IDH3A is linked to glioblastoma.